Protein degradation by the ubiquitin-proteasome pathway in normal and disease states

Journal of the American Society of Nephrology

Volumn 17, Issue 7, 2006, Pages 1807-1819

  Lecker, Stewart H ^a   Goldberg, Alfred L ^a   Mitch, William E ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE 3; CELL PROTEIN; EPOXYMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LACTACYSTIN; MUSCLE PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER THERAPY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME MECHANISM; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION; UBIQUITIN PROTEASOME PATHWAY; UREMIA;

EID: 33745816760     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006010083     Document Type: Review

References (110)

1. Mitch WE, Goldberg AL: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome system. N Engl J Med 335: 1897-1905, 1996
2. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell 78: 761-771, 1994
3. Baehrecke EH: Autophagy: Dual roles in life and death? Nat Rev Mol Cell Biol 6: 505-510, 2005
4. Lardeux BR, Mortimore GE: Amino acid and hormonal control of macromolecular turnover in perfused rat liver. Evidence for selective autophagy. J Biol Chem 262: 14514-14519, 1987
5. Gronostajski RM, Goldberg AL, Pardee AB: The role of increased proteolysis in the atrophy and arrest of cell division in fibroblasts following serum deprivation. J Cell Biol 121: 189-198, 1984
6. Goll DE, Thompson VF, Li H, Wei W, Cong J: The calpain system. Physiol Rev 83: 731-801, 2003
7. Salvesen GS, Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell 91: 443-446, 1997
8. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82: 373-428, 2002
9. Pickart CM: Back to the future with ubiquitin. Cell 116: 181-190, 2004
10. Baumeister W, Walz J, Zuhl F, Seemuller E: The proteasome: Paradigm of a self-compartmentalizing protease. Cell 92: 367-380, 1998
11. Muratani M, Tansey WP: How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 4: 192-201, 2003
12. Lipford JR, Smith GT, Chi Y, Deshaies RJ: A putative stimulatory role for activator turnover in gene expression. Nature 438: 113-116, 2005
13. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-kappaB activity. Annu Rev Immunol 18: 621-663, 2000
14. Jensen TJ, Loo MA, Find S, Williams DB, Goldberg AL, Riordan JR: Multiple proteolytic systems, including the proteasome contribute CFTR processing. Cell 83: 129-135, 1995
15. Ward CL, Omura S, Kopito RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83: 121-127, 1995
16. Meusser B, Hirsch C, Jarosch E, Sommer T: ERAD: The long road to destruction. Nat Cell Biol 7: 766-772, 2005
17. Hicke L, Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19: 141-172, 2003
18. Sigismund S, Polo S, Di Fiore PP: Signaling through monoubiquitination. Curr Top Microbiol Immunol 286: 149-185, 2004
19. Haas AL, Rose IA: The mechanism of ubiquitin activating enzyme. A kinetic and equilibrium analysis. J Biol Chem 257: 10329-10337, 1982
20. Handley PM, Mueckler M, Siegel NR, Ciechanover A, Schwartz AL: Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proc Natl Acad Sci U S A 88: 258-262, 1991
21. Jentsch S: The ubiquitin-conjugation system. Annu Rev Genet 26: 179-207, 1992
22. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, Reimann JD: The lore of the RINGs: Substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 10: 429-439, 2000
23. Ingham RJ, Gish G, Pawson T: The Nedd4 family of E3 ubiquitin ligases: Functional diversity within a common modular architecture. Oncogene 23: 1972-1984, 2004
24. Scheffner M, Nuber U, Huibregtse JM: Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373: 81-83, 1995
25. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM: A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A 92: 5249, 1995
26. Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, Eichele G, Beaudet AL: Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet 17: 75-78, 1997
27. Malik B, Schlanger L, Al-Khalili O, Bao H-F, Yue G, Price SR, Mitch WE, Eaton DC: ENaC degradation in A6 cells by the ubiquitin-proteasome proteolytic pathway. J Biol Chem 276: 12903-12910, 2001
28. Kamynina E, Debonneville C, Hirt RP, Staub O: Liddle's syndrome: A novel mouse Nedd4 isoform regulates the activity of the epithelial Na(+) channel. Kidney Int 60: 466-471, 2001
29. Petroski MD, Deshaies RJ: Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6: 9-20, 2005
30. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM: RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 96: 11364-11369, 1999
31. Seol JH, Feldman RM, Zachariae W, Shevchenko A, Correll CC, Lyapina S, Chi Y, Galova M, Claypool J, Sandmeyer S, Nasmyth K, Deshaies RJ, Shevchenko A, Deshaies RJ: Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev 13: 1614-1626, 1999
32. Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ: The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 2: 439-451, 1996
33. 32a. Varshavsky A, Turner G, Du F, Xie Y: Felix Hoppe-Seyler Lecture 2000: The ubiquitin system and the N-end rule pathway. Biol Chem 381: 779-789, 2000
34. Rao H, Uhlmann F, Nasmyth K, Varshavsky A: Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability. Nature 410: 955-959, 2001
35. Hu RG, Sheng J, Qi X, Xu Z, Takahashi TT, Varshavsky A: The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. Nature 437: 981-986, 2005
36. Lecker SH, Jagoe RT, Gomes M, Baracos V, Bailey JL, Price SR, Mitch WE, Goldberg AL: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004
37. Kaelin WG Jr: How oxygen makes its presence felt. Genes Dev 16: 1441-1445, 2002
38. Hatakeyama S, Nakayama KI: U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 302: 635-645, 2003
39. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C: Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 114: 1058-1071, 2004
40. Voges D, Zwickl P, Baumeister W: The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068, 2000
41. Kisselev AF, Goldberg AL: Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8: 739-758, 2001
42. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D: A gated channel into the proteasome core particle. Nat Struct Biol 7: 1062-1067, 2000
43. Goldberg AL: Nobel committee tags ubiquitin for distinction. Neuron 45: 339-344, 2005
44. Benaroudj N, Zwickl P, Seemuller E, Baumeister W, Goldberg AL: ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol Cell 11: 69-78, 2003
45. Schmidt M, Hanna J, Elsasser S, Finley D: Proteasome-associated proteins: Regulation of a proteolytic machine. Biol Chem 386: 725-737, 2005
46. Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003
47. Smith DM, Kafri G, Cheng Y, Ng D, Walz T, Goldberg AL: ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol Cell 20: 687-698, 2005
48. Kisselev AF, Akopian TN, Woo KM, Goldberg AL: The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 274: 3363-3371, 1999
49. Reits E, Neijssen J, Herberts C, Benckhuijsen W, Janssen L, Drijfhout JW, Neefjes J: A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20: 495-506, 2004
50. Saric T, Graef CI, Goldberg AL: Pathway for degradation of peptides generated by proteasomes: A key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279: 46723-46732, 2004
51. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappaB1 precursor protein and the activation of NF-kappaB. Cell 78: 773-785, 1994
52. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL: Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14: 95-104, 2004
53. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004
54. Shastri N, Schwab S, Serwold T: Producing nature's gene-chips: The generation of peptides for display by MHC class I molecules. Annu Rev Immunol 20: 463-493, 2002
55. Rock KL, York IA, Saric T, Goldberg AL: Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80: 1-70, 2002
56. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL: Viral subversion of the immune system. Annu Rev Immunol 18: 861-926, 2000
57. Rock KL, York IA, Goldberg AL: Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5: 670-677, 2004
58. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL: An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3: 1169-1176, 2002
59. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL: The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 3: 1177-1184, 2002
60. Gaczynska M, Rock KL, Spies T, Goldberg AL: Peptidase activities of proteasomes are differentially regulated by the MHC-encoded genes LMP2 and LMP7. Proc Natl Acad Sci U S A 91: 9213-9217, 1994
61. Cascio P, Call M, Petre BM, Walz T, Goldberg AL: Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J 21: 2636-2645, 2002
62. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53: 773-782, 1998
63. Kopple JD: National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 37: S66-S70, 2001
64. Mitch WE: Malnutrition: A frequent misdiagnosis for hemodialysis patients. J Clin Invest 110: 437-439, 2002
65. Kaysen GA, Dubin JA, Muller H-G, Rosales L, Levin NW, Mitch WE: Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int 65: 1408-1415, 2004
66. Lim VS, Kopple JD: Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int 58: 1-10, 2000
67. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE: The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent, ubiquitin-proteasome pathway. J Clin Invest 97: 1447-1453, 1996
68. Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J: Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61: 1286-1292, 2002
69. Mansoor O, Beaufrere Y, Boirie Y, Ralliere C, Taillandier D, Aurousseau E, Schoeffler P, Arnal M, Attaix D: Increased mRNA levels for components of the lysosomal, Ca++-activated and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proc Natl Acad Sci U S A 93: 2714-2718, 1996
70. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasseigren P-O: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99: 163-168, 1997
71. Williams AB, Sun X, Fischer JE, Hasseigren P-O: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126: 744-749, 1999
72. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS, Mitch WE: Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome pathway by a mechanism including gene transcription. J Clin Invest 98: 1703-1708, 1996
73. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR: Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 276: C1132-C1138, 1999
74. Tawa NE, Odessey R, Goldberg AL: Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 100: 197-203, 1997
75. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clark BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuel DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001
76. Sandri M, Sandri C, Gilbert A, Skuck C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004
77. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Klinenber JR, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403, 2004
78. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL: IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol 287: E591-E601, 2004
79. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA: Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 280: 2847-2856, 2005
80. Serrano AL, Murgia M, Pallafacchina G, Calabria E, Coniglio P, Lomo T, Schiaffino S: Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth. Proc Natl Acad Sci U S A 98: 13108-13113, 2001
81. McElhinny AS, Kakinuma K, Sorimachi H, Labeit S, Gregorio CC: Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 157: 125-136, 2002
82. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C: Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin 1. Proc Natl Acad Sci U S A 101: 18135-18140, 2004
83. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE: Regulation of muscle protein degradation: Coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15: 1537-1545, 2004
84. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285-298, 2004
85. Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, Bannon AW, Boyle WJ, Lacey DL, Han HQ: Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res 64: 8193-8198, 2004
86. Solomon V, Goldberg AL: Importance of the ATP-ubiquitin-proteasome pathway in degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 271: 26690-26697, 1996
87. Varshavsky A: The N-end rule: Functions, mysteries, uses. Proc Natl Acad Sci U S A 93: 12142-12149, 1996
88. Solomon V, Baracos V, Sarraf P, Goldberg AL: Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. Proc Natl Acad Sci U S A 95: 12602-12607, 1998
89. Lecker SH, Solomon V, Price SR, Kwon YT, Mitch WE, Goldberg AL: Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest 104: 1411-1420, 1999
90. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spielgelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665-668, 1996
91. DeFronzo RA, Beckles AD: Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236: E328-E334, 1979
92. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
93. Du J, Wang X, Meireles CL, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE: Activation of caspase 3 is an initial step triggering muscle proteolysis in catabolic conditions. J Clin Invest 113: 115-123, 2004
94. Song Y-H, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P: Muscle-specific expression of insulin-like growth factor-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115: 451-458, 2005
95. Workeneh BT, Rondon-Berrios H, Ayehu G, Hu Z, Ferrando A, Wang H, Kopple JD, Du J, Mitch WE: Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions, including kidney failure [Abstract]. J Am Soc Nephrol 16: 713A, 2005
96. Wei W, Fareed MU, Evenson A, Menconi MJ, Yang H, Petkova V, Hasselgren PO: Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. Am J Physiol Regul Integr Comp Physiol 288: R580-R590, 2005
97. Tidball JG, Spencer MJ: Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J Physiol 545: 819-828, 2002
98. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation and atherosclerosis in chronic kidney failure. Kidney Int 55: 1899-1911, 1999
99. Mitch WE, Medina R, Greiber S, May RC, England BK, Price SR, Bailey JL, Goldberg AL: Metabolic acidosis stimulates muscle protein degradation by activating the ATP-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 93: 2127-2133, 1994
100. May RC, Bailey JL, Mitch WE, Masud T, England BK: Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo. Kidney Int 49: 679-683, 1996
101. Wang XH, Hu JP, Hu Z, Du J, Mitch WE: Diabetes in db/db mice causes muscle atrophy via the ubiquitin-proteasome system and is reversed by rosiglitazone administration [Abstract]. J Am Soc Nephrol 16: 632A, 2005
102. Saad MJA, Folli F, Kahn JA, Kahn CR: Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92: 2065-2072, 1993
103. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190, 2005
104. Bailey JL, Price SR, Xhang B, Mitch WE: Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: Implications for muscle atrophy. J Am Soc Nephrol 17: 1388-1394, 2006
105. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD: Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019, 2001
106. Hunter RB, Kandarian SC: Disruption of either the NFKB1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114: 1504-1511, 2004
107. Tran H, Brunet A, Griffith EC, Greenberg ME: The many forks in FOXO's road. Sci STKE 2003: RE5, 2003
108. Dardevet DD, Sornet C, Taillandier D, Savary I, Attaix D, Grizard J: Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats: Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J Clin Invest 96: 2113-2119, 1995
109. Wing SS, Goldberg AL: Glucocorticoids activate the ATP-ubiquitin- dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 264: E668-E676, 1993
110. Price SR, England BK, Bailey JL, Van Vreede K, Mitch WE: Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am J Physiol 267: C955-C960, 1994